Elanco Animal Health Inc.’s stock was headed for an 18-month high early Monday, after the company said it has agreed to sell its aqua business to Merck Animal Health for $1.3 billion in cash in a move aimed at helping it focus on promising pipeline products.
Greenfield, Ind.-based Elanco
which makes products to protect the health of farm animals and pets, said the sum is equal to about 7.4 times the estimated 2023 revenue of the Elanco aqua business, which includes products across warm-water and cold-water species such as salmon vaccines.
The deal “allows us to prioritize our investments in larger markets with greater earnings potential over the medium and long term, while creating balance sheet flexibility,” Jeff Simmons, president and chief executive of Elanco Animal Health, said in a statement.
The aqua business had about $175 million in revenue in 2023. The divestiture includes currently marketed brands; aqua R&D projects; the transfer of manufacturing sites in Prince Edward Island, Canada and Dong Nai, Vietnam; and about 280 commercial and manufacturing employees.
Elanco will use the proceeds of the deal to pay down debt and reduce its interest costs by about $65 million a year, or 11 cents of per-share earnings.
The deal is expected to close around midyear.
Elanco has six potential blockbuster products expected in the U.S. market by 2025. It expects approvals for Credelio Quattro, Zenrelia and Bovaer in the first half of 2024.
Credelio Quattro is a parasiticide for dogs, Zenrelia is a skin treatment for dogs and Bovaer is a methane-reducing product for cattle.
“Additionally, the company is opportunistically pursuing platform-aligned targets, such as monoclonal antibodies, and other major emerging spaces of high unmet need,” said the statement.
Elanco will provide further details of the deal when it releases fourth-quarter earnings on Feb. 26.
Elanco’s stock was up 6% premarket and has gained 6.2% in the last 12 months through Friday’s close, while the S&P 500
has gained 19.9%.